Dompe Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dompe Farmaceutici SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10825
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dompe Farmaceutici SpA (Dompe) is a developer of therapeutic solutions that research novel therapies for the treatment of rare and orphan diseases. The company provides product pipeline such as C5aR Antagonists, TRPM8 Blockers pain, TRPM8 Blockers urology, BKB1R Antagonists, CNR2 Agonists and GPR120 Agonists, among others. It offers treatment in the therapeutic areas of respiratory diseases, chronic obstructive pulmonary disease, pulmonary arterial hypertension, cystic fibrosis, osteoarticular solutions, pain therapy and dentistry, among others. Dompe’s target research areas include respiratory diseases, oncology, diabetology, ophthalmology, organ transplantation, chronic obstructive pulmonary disease and pulmonary arterial hypertension, among others. The company has operations in the US and Albania. Dompe is headquartered in Milan, Italy.

Dompe Farmaceutici SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Dompe Farmaceutici to Acquire Pharma Division of Bracco 10
Partnerships 11
Bracco Imaging Enters into Agreement with Shanghai Pharma 11
Lubris Biopharma Enters into Agreement with Dompe Farmaceutici 12
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 13
Dompe Farmaceutici Enters Into Co-Development Agreement With SatRx For Reparixin 14
Licensing Agreements 15
MolMed and Dompe Expand Licensing and Distribution Agreement 15
Debt Offering 16
Bracco Imaging Raises USD124.6 Million in Private Placement of 3.17% Notes Due 2021 16
Asset Transactions 17
Dompe Farmaceutici to Acquire Pharma Division of Bracco 17
Acquisition 18
Dompe Acquires Remaining 51% Stake In Anabasis 18
Dompe Farmaceutici SpA – Key Competitors 19
Dompe Farmaceutici SpA – Key Employees 20
Dompe Farmaceutici SpA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dompe Farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dompe Farmaceutici to Acquire Pharma Division of Bracco 10
Bracco Imaging Enters into Agreement with Shanghai Pharma 11
Lubris Biopharma Enters into Agreement with Dompe Farmaceutici 12
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 13
Dompe Farmaceutici Enters Into Co-Development Agreement With SatRx For Reparixin 14
MolMed and Dompe Expand Licensing and Distribution Agreement 15
Bracco Imaging Raises USD124.6 Million in Private Placement of 3.17% Notes Due 2021 16
Dompe Farmaceutici to Acquire Pharma Division of Bracco 17
Dompe Acquires Remaining 51% Stake In Anabasis 18
Dompe Farmaceutici SpA, Key Competitors 19
Dompe Farmaceutici SpA, Key Employees 20
Dompe Farmaceutici SpA, Other Locations 21
Dompe Farmaceutici SpA, Subsidiaries 21

List of Figures
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Dompe Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LeasePlan Corporation N.V.:企業の戦略・SWOT・財務情報
    LeasePlan Corporation N.V. - Strategy, SWOT and Corporate Finance Report Summary LeasePlan Corporation N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • J. C. Penney Company, Inc.:企業の戦略・SWOT・財務情報
    J. C. Penney Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary J. C. Penney Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cellestia Biotech AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Cellestia Biotech AG (Cellestia Biotech) is a biopharmaceutical company that develops anti-cancer drugs for the treatment of oncology and immunological disorders. The company's lead compound includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymp …
  • Giraffas Administradora De Franquias Ltda:企業の戦略・SWOT・財務情報
    Giraffas Administradora De Franquias Ltda - Strategy, SWOT and Corporate Finance Report Summary Giraffas Administradora De Franquias Ltda - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • RPC Group PLC:企業の戦略・SWOT・財務情報
    RPC Group PLC - Strategy, SWOT and Corporate Finance Report Summary RPC Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Newell Brands Inc (NWL):企業の財務・戦略的SWOT分析
    Newell Brands Inc (NWL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PT Lotte Shopping Indonesia:企業の戦略・SWOT・財務分析
    PT Lotte Shopping Indonesia - Strategy, SWOT and Corporate Finance Report Summary PT Lotte Shopping Indonesia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • KemPharm Inc (KMPH):製薬・医療:M&Aディール及び事業提携情報
    Summary KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the …
  • Mitsubishi Tanabe Pharma Corporation:企業のM&A・事業提携・投資動向
    Mitsubishi Tanabe Pharma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsubishi Tanabe Pharma Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • AVJennings Limited:企業の戦略・SWOT・財務情報
    AVJennings Limited - Strategy, SWOT and Corporate Finance Report Summary AVJennings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mayo Clinic-医療機器分野:企業M&A・提携分析
    Summary Mayo Clinic (Mayo) is a not-for-profit medical practice and medical research organization. It provides comprehensive medical facilities and programs related to patient care services, research and medical education. It offers specialized medical care with medical departments and centers in mo …
  • Westinghouse Electric Company LLC:電力:M&Aディール及び事業提携情報
    Summary Westinghouse Electric Company, LLC (Westinghouse) a subsidiary of Toshiba Corporation, is a nuclear energy company. It offers nuclear plant products, technologies, nuclear fuel, plant design and related services to utilities across the world. The company conducts the development, licensing, …
  • Acuity Brands, Inc.:企業の戦略・SWOT・財務分析
    Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • MAX Resource Corp. (MXR):企業の財務・戦略的SWOT分析
    MAX Resource Corp. (MXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Synedgen Inc:医療機器:M&Aディール及び事業提携情報
    Summary Synedgen Inc (Synedgen) is a biotechnology company that discovers and develops polysaccharide-based drugs, which enhance and mimic the innate immune system. The company’s pipeline products include SYGN305, SYGN399, SYGN303, SYGN313 and SYGN309. Synedgen develops products for the treatment of …
  • Choppies Enterprises Limited (CHOPPIES):企業の財務・戦略的SWOT分析
    Choppies Enterprises Limited (CHOPPIES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • National Real Estate Company K.S.C.:企業の戦略・SWOT・財務情報
    National Real Estate Company K.S.C. - Strategy, SWOT and Corporate Finance Report Summary National Real Estate Company K.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • BEKB | BCBE Private Banking:企業の戦略・SWOT・財務情報
    BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report Summary BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NKT AS (NKT):企業の財務・戦略的SWOT分析
    NKT AS (NKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Cyclenium Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cyclenium Pharma Inc (Cyclenium Pharma) is a pharmaceutical research and development company that offers small molecule therapeutics agent producer for drug discovery. The company employs its proprietary customized macrocycles for recognition of topologies technology for discovering and deve …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆